| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97bd68cb0a98913a5940c708e7ce1679 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1251
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57438
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2018-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3bf4414871e46e1a48c4becf27cc2ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfc3bddec7a8d6b1da64a69aad15acad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bc6274fac45d3059a2a6490e0141ec8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b4c82c7d33748441c5a938f88a034c6 |
| publicationDate |
2019-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019108135-A9 |
| titleOfInvention |
A system and method for classifying cancer patients into appropriate cancer treatment groups and compounds for treating the patient |
| abstract |
A method for the prognosis of response to treatment for a patient suffering from cancer, the method comprising: measuring the expression of at least one immune marker in a leukocyte sample taken from the patient with cancer; classifying the patient sample into (i) sustainable responders (SR) to selective internal radiation therapy (SIRT) or (ii) transient/non-responders (TR/NR) to (SIRT) based on expression of the at least one immune marker in relation to a predetermined value and treating sustainable responders (SR) to SIRT or SIRT or a composition comprising SIRT and an immunotherapy. In a preferred embodiment, the method is for the prognosis of response to treatment of a Hepatocellular carcinoma (HCC) patient comprising detecting the co-expression of PD-1 or Tim-3 with CCR5; or expression of PD-1, Tim-3, CXCR6, or combinations thereof in a leukocyte sample taken from the patient. |
| priorityDate |
2017-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |